微卫星稳定转移性结直肠癌的免疫治疗反应受转移部位影响
本研究评估了化疗难治性结直肠癌患者接受REGONIVO或RIN方案后,转移部位对疗效的影响。96例患者中,肝或腹膜转移者ORR为0%,仅肺转移者ORR为56.3%、PFS为14个月。结论认为REGONIVO和RIN在仅肺转移者中最活跃,肝和腹膜转移者耐药。
要点
- 肝或腹膜转移者ORR为0%,中位PFS分别为2.0和1.5个月。
- 仅肺转移者ORR为56.3%,PFS为14个月。
- 肺转移者合并淋巴结或其他肝外转移会减弱但不阻止缓解。
核心结论
- REGONIVO和RIN在仅肺转移的微卫星稳定转移性结直肠癌中最活跃,肝和腹膜转移者耐药。
研究设计与样本
- 评估接受REGONIVO或RIN治疗的化疗难治性结直肠癌患者,共96例(REGONIVO 58例,RIN 38例),基于转移部位分析2个月器官特异性反应、ORR、PFS和OS。
主要发现
- 肝或腹膜转移导致不良结局,ORR为0%,中位PFS分别为2.0和1.5个月。
- 仅肺转移者ORR为56.3%,PFS为14个月。
- 肺转移疾病患者合并淋巴结或其他肝外转移疾病会减弱但不阻止缓解。
- 2个月反应评估显示肺部、软组织和远处淋巴结有活性。
临床怎么用
- 作者认为未来微卫星稳定结直肠癌的检查点抑制剂试验应根据转移部位对患者进行分层。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prior studies indicate that colorectal cancer patients with liver metastases did not benefit from regorafenib, nivolumab (REGONIVO) or regorafenib, ipilimumab, nivolumab (RIN) treatments, while those without liver metastases showed significant response. This study explores the impact of metastatic sites on treatment outcomes. METHODS: Chemotherapy-refractory colorectal cancer patients treated with REGONIVO or RIN were evaluated, focusing on 2-month organ-specific response, ORR, PFS and OS based on metastatic sites. RESULTS: Of the 96 patients analyzed (58 REGONIVO, 38 RIN), liver or peritoneal metastases led to poor outcomes, with 0 % ORR, and median PFS of 2.0 and 1.5 months respectively. In contrast, lung-only metastases had an ORR of 56.3 % and a PFS of 14 months. The presence of concurrent LN or other extrahepatic metastatic disease in patients with lung metastatic disease diminished but did not prohibit responses. The 2-month response assessment revealed activity in the lungs, soft tissues, and distant lymph nodes. CONCLUSIONS: REGONIVO and RIN were most active in lung-only metastases. Liver and peritoneal metastases were resistant. Future checkpoint inhibitor trials in MSS colorectal cancer should stratify patients based on metastatic locations.
引用
- Fakih M, Wang C, Sandhu J, et al. Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases. Eur J Cancer. 2023. PMID: 37980853. doi:10.1016/j.ejca.2023.113437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。